回生口服液联合肝动脉化疗栓塞术治疗原发性肝癌56例临床剖析.docVIP

回生口服液联合肝动脉化疗栓塞术治疗原发性肝癌56例临床剖析 　　doi：10.3969/j.issn.1007-614x.2014.17.46 　　摘要目的：评价回生口服液结合肝动脉化疗栓塞术治疗原发性肝癌的疗效。方法：将56例原发性肝癌患者随机分为治疗组30例和对照组26例，两组患者均行肝动脉灌注化疗栓塞术，治疗组加口服回生口服液。结果：两组患者有效率分别为63.3%和46.15%，生活质量比较分别为53%和46%。结论：回生口服液联合肝动脉灌注化疗栓塞术治疗中晚期原发性肝癌可以控制肿瘤病情，提高患者生存质量。 　　关键词回生口服液肝动脉化疗栓塞术原发性肝癌 　　Clinical analysis of 56 cases with primary carcinoma of the liver treated by huisheng oral liquid combined with hepatic arterial chemoembolization 　　Liang Fang，Zhang Lijuan，Zhang Qingsong，Li Jingmei，Xing Guochen 　　Department of Oncology，Zhengzhou Central Hospital Affiliated to Zhengzhou University 450000 　　AbstractObjective：To evaluate the effect of huisheng oral liquid combined with hepatic arterial chemoembolization treated on primary carcinoma of the liver.Methods：56 cases with primary carcinoma of the liver were randomly divided into the treatment group with 30 cases and the control group with 26 cases.Two groups were treated with hepatic arterial chemoembolization，and the treatment group also were given huisheng oral liquid.Results：The efficiency in the treatment group and the control group were 63.3% and 46.15% respectively，and the quality of life in two groups were 53% and 46% respectively.Conclusion：The treatment of huisheng oral liquid combined with hepatic arterial chemoembolization on advanced primary hepatocellular carcinoma can control tumor disease of patients，and improve their quality of life. 　　Key wordsHuisheng oral liquid；Hepatic arterial chemoembolization；Primary carcinoma of the liver 　　原发性肝癌是一种恶性程度很高的临床常见恶性肿瘤，病情进展迅速，疾病早期缺乏特异性的临床表现，不易早期确诊和治疗，因此该病的生存期短，预后差。对于中晚期的患者多采用综合治疗方法，主要治疗手段是肝动脉化疗栓塞术。2009年8月-2013年12月收治原发性肝癌，对于无法手术的中晚期患者采用回生口服液联合肝动脉化疗栓塞术治疗，提高了患者的治疗有效率，有效改善患者生存质量，现报告如下。 　　资料与方法 　　2009年8月-2013年12月收治原发性肝癌56例，随机分为治疗组和对照组。治疗组30例，男23例，女7例，年龄30～75岁，平均52.5岁，AFP升高者25例。对照组26例，男20例，女6例，年龄32～70岁，平均51岁，23例患者的AFP升高。两组一般资料比较差异无统计学意义，P0.05，具有可比性。 　　诊断标准：参照《临床诊疗指南》中原发型肝癌的诊断标准[1]，根据临床症状、CT或MRI检查结果、血清AFP检测结果等资料确诊为不能手术的中晚期肝癌。 　　纳入标准：①郑州市中心医院在此期间经临床CT及AFP测定，或者肝脏穿刺细胞学确诊